Active Substance Master File (ASMF) system in EU MCQs With Answer

Active Substance Master File (ASMF) system in EU MCQs With Answer

Introduction: The Active Substance Master File (ASMF) system in the EU is a regulatory mechanism allowing active substance manufacturers to provide detailed quality information to regulators while protecting confidential manufacturing know‑how. This system splits information into an Open Part and a Restricted Part; the applicant (MAH) assembles the marketing‑authorisation dossier using the Open Part and a Letter of Access to the Restricted Part supplied by the manufacturer. ASMF is widely used for generics, hybrids and other applications where the manufacturer wants to safeguard proprietary process details, and its correct use is essential for lifecycle management, variations and inspections.

Q1. What is the primary purpose of the ASMF system in the EU?

• To protect confidential manufacturing information while allowing marketing‑authorisation holders and regulators access to necessary quality data
• To set price controls for active substances across EU member states
• To replace Certificates of Suitability (CEPs) for all substances
• To act as a substitute for clinical trial applications

Correct Answer: To protect confidential manufacturing information while allowing marketing‑authorisation holders and regulators access to necessary quality data

Q2. The ASMF dossier is conventionally divided into which two main parts?

• Open Part (for MAH/regulators) and Restricted Part (for manufacturer confidential data)
• Module 1 and Module 3 only
• Clinical Part and Nonclinical Part
• Administrative Part and Financial Part

Correct Answer: Open Part (for MAH/regulators) and Restricted Part (for manufacturer confidential data)

Q3. Which document is commonly considered an alternative to submitting an ASMF when available?

• Certificate of Suitability (CEP) issued by the EDQM
• Investigator’s Brochure
• Pharmacovigilance System Master File (PSMF)
• Clinical Study Report (CSR)

Correct Answer: Certificate of Suitability (CEP) issued by the EDQM

Q4. Which party typically submits the Open Part of the ASMF to the competent authorities?

• The marketing‑authorisation holder (applicant) submits the Open Part and relies on a Letter of Access for the Restricted Part
• The active substance manufacturer submits the full ASMF directly to each member state
• The EDQM submits the ASMF on behalf of the manufacturer
• No submission is required; only verbal confirmation is sufficient

Correct Answer: The marketing‑authorisation holder (applicant) submits the Open Part and relies on a Letter of Access for the Restricted Part

Q5. What is the primary purpose of a Letter of Access in the ASMF system?

• To permit a marketing‑authorisation holder to refer to the manufacturer’s Restricted Part and to allow assessors access to confidential data
• To certify GMP compliance of the manufacturing site
• To transfer patent rights from the manufacturer to the MAH
• To indicate the price of the active substance

Correct Answer: To permit a marketing‑authorisation holder to refer to the manufacturer’s Restricted Part and to allow assessors access to confidential data

Q6. In which section of the Common Technical Document (CTD) is ASMF content normally included?

• Module 3.2.S (Quality of the Active Substance)
• Module 2.5 (Overview of Nonclinical Studies)
• Module 1.0 (Administrative Information)
• Module 4.2 (Clinical Pharmacology)

Correct Answer: Module 3.2.S (Quality of the Active Substance)

Q7. Which statement best describes the primary difference between the EU ASMF and the US DMF?

• The ASMF is a two‑part EU system (Open/Restricted) facilitating MAH access; the US DMF is submitted to FDA by the manufacturer with different access and administrative arrangements
• The ASMF is only for biologicals while the DMF is only for small molecules
• The DMF automatically grants marketing authorisation in the EU
• The ASMF is a public document and the DMF is always confidential

Correct Answer: The ASMF is a two‑part EU system (Open/Restricted) facilitating MAH access; the US DMF is submitted to FDA by the manufacturer with different access and administrative arrangements

Q8. Which of the following is typically found in the Restricted Part of the ASMF?

• Detailed manufacturing process, in‑process controls, validation data and impurity profiles
• Summary of specifications and non‑confidential stability results only
• Administrative correspondence between MAH and CMS
• Public labelling and package leaflet texts

Correct Answer: Detailed manufacturing process, in‑process controls, validation data and impurity profiles

Q9. Which information is normally included in the Open Part of an ASMF?

• General substance information, controls and specifications summaries, method summaries and stability summary (non‑confidential)
• Full validated analytical procedures including chromatographic conditions and columns
• Detailed batch manufacturing records with site identities
• Supplier invoices and pricing details

Correct Answer: General substance information, controls and specifications summaries, method summaries and stability summary (non‑confidential)

Q10. For which types of marketing‑authorisation applications is the ASMF commonly used?

• Generic, hybrid and other MA applications where the active substance manufacturer wishes to protect proprietary manufacturing information
• Only for orphan drug applications
• Only for veterinary products
• Only for centrally authorised biologics

Correct Answer: Generic, hybrid and other MA applications where the active substance manufacturer wishes to protect proprietary manufacturing information

Q11. How is confidentiality of the Restricted Part ensured during regulatory assessment?

• By the Letter of Access procedure and by restricting assessor access to the Restricted Part without disclosure to the MAH
• By publishing the Restricted Part on the EMA website
• By removing all impurity data before submission
• By replacing the Restricted Part with a CEP automatically

Correct Answer: By the Letter of Access procedure and by restricting assessor access to the Restricted Part without disclosure to the MAH

Q12. If an active substance manufacturer changes a critical manufacturing step after ASMF submission, what is the appropriate regulatory action?

• The MAH should submit a variation application updating the ASMF information and the Restricted Part as required
• No action is required if the Open Part remains unchanged
• The MAH must withdraw the marketing authorisation immediately
• A new ASMF cannot be submitted for the same substance

Correct Answer: The MAH should submit a variation application updating the ASMF information and the Restricted Part as required

Q13. Can one ASMF be used by multiple marketing‑authorisation holders?

• Yes, the manufacturer can grant Letters of Access to multiple MAHs allowing the same ASMF to be referenced
• No, each MAH requires a separate ASMF from the manufacturer
• Only if the MAHs are in the same member state
• Only if EDQM approves the transfer

Correct Answer: Yes, the manufacturer can grant Letters of Access to multiple MAHs allowing the same ASMF to be referenced

Q14. Who performs the scientific assessment of the ASMF during a decentralised or national MA procedure?

• The assessor(s) in the competent authority(ies) evaluating the marketing‑authorisation application (RMS/CMS or national assessor)
• The EDQM Central Office
• The European Parliament
• The World Health Organization

Correct Answer: The assessor(s) in the competent authority(ies) evaluating the marketing‑authorisation application (RMS/CMS or national assessor)

Q15. Who holds the ultimate legal responsibility for the quality and suitability of the active substance used in a finished product when an ASMF is referenced?

• The marketing‑authorisation holder remains legally responsible for the finished product quality and for justifying the suitability of the active substance
• The active substance manufacturer assumes full legal responsibility for the MA
• The EDQM is legally responsible once a Letter of Access is issued
• The exporting customs authority is responsible

Correct Answer: The marketing‑authorisation holder remains legally responsible for the finished product quality and for justifying the suitability of the active substance

Q16. What is an important advantage of an ASMF compared with a CEP?

• An ASMF allows the manufacturer to retain confidential process details while supplying regulators with full quality data
• An ASMF automatically replaces the need for GMP inspections
• An ASMF eliminates the need for any stability data
• An ASMF is accepted worldwide without any assessment

Correct Answer: An ASMF allows the manufacturer to retain confidential process details while supplying regulators with full quality data

Q17. Where are detailed validated analytical procedures normally placed in the ASMF?

• In the Restricted Part to protect proprietary method details
• In the Open Part for full public disclosure
• In Module 1 only
• Only in the CEP, never in the ASMF

Correct Answer: In the Restricted Part to protect proprietary method details

Q18. Which activities are part of ASMF lifecycle management after initial submission?

• Reporting of variations, updates to stability and specifications, GMP re‑inspection outcomes and communication of manufacturing changes
• Only a one‑time submission with no subsequent updates allowed
• Transfer of the ASMF to the EDQM for permanent storage
• Conversion of the ASMF into a public monograph immediately

Correct Answer: Reporting of variations, updates to stability and specifications, GMP re‑inspection outcomes and communication of manufacturing changes

Q19. When is a CEP generally preferred over submitting an ASMF?

• When the active substance manufacturer seeks a single EDQM certificate demonstrating compliance with the European Pharmacopoeia monograph across multiple MA procedures
• When the manufacturer wants to withhold all analytical data from regulators
• When the substance is not described in any pharmacopoeia
• When the MAH prefers to omit stability data from the dossier

Correct Answer: When the active substance manufacturer seeks a single EDQM certificate demonstrating compliance with the European Pharmacopoeia monograph across multiple MA procedures

Q20. What is the role of the EDQM in relation to active substance quality and the ASMF system?

• The EDQM issues CEPs and conducts inspections related to Certificates of Suitability but does not directly assess private ASMF Restricted Parts for marketing authorisations
• The EDQM centrally assesses all ASMFs before any national authority may review them
• The EDQM prepares the Open Part of every ASMF
• The EDQM grants marketing authorisations based on the ASMF

Correct Answer: The EDQM issues CEPs and conducts inspections related to Certificates of Suitability but does not directly assess private ASMF Restricted Parts for marketing authorisations

Download